Heather L. McArthur

Heather L. McArthur

Auto-generated profile, based on publicly available information

Heather L. McArthur

Cedars-Sinai Medical Center, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2019 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
JFJeremy Force
Jeremy Force
JLJorge Henrique Santos Leal
Jorge Henrique Santos Leal
HMHeather L. McArthur
Heather L. McArthur

16 March 2021 in Clinical Breast Cancer
Verified
Journal Article
Open access
ANAnthony T. Nguyen
Anthony T. Nguyen
SSStephen L. Shiao
Stephen L. Shiao
HMHeather L. McArthur
Heather L. McArthur
Breast irradiation has long been utilized in the adjuvant or metastatic setting to eliminate microscopic disease or to palliate existing disease, respectively. However, preclinical data have demonstrated that radiation can also alter the tumor microenvironment and induce antitumor immune responses. As a result, multiple clinical studies have been undertaken and have reported synergy between radiation and immune checkpoint blockade across various cancer types. Given recent clinical successes with immune checkpoint blockade in both early-stage and metastatic breast cancer, there has been substantial interest in combining radiation and immunotherapy to enhance local and systemic immune responses. Herein, we review the preclinical rationale for combining radiotherapy and immunotherapy, the early clinical trials that have adopted this strategy in breast cancer, and the landscape of ongoing relevant clinical trials. Finally, we propose future directions based on promising preclinical studies that integrate radiation, checkpoint blockade, and novel agents for the treatment of breast cancer.

16 April 2018 in Current Breast Cancer Reports
Verified
Journal Article
Open access
PDF file
ZHZishuo I. Hu
Zishuo I. Hu
HMHeather L. McArthur
Heather L. McArthur
Purpose of review This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.


1 March 2016 in Current Problems in Cancer
Verified
Journal Article
Closed access
KSKatherine Sanchez
Katherine Sanchez
DPDavid Page
David Page
HMHeather L. McArthur
Heather L. McArthur

6 October 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
DPDavid B. Page
David B. Page
HWHannah Wen
Hannah Wen
EBEdi Brogi
Edi Brogi
DDDana Dure
Dana Dure
DRDara Ross
Dara Ross
HMHeather L. McArthur
Heather L. McArthur